Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Pfizer Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


An examination of short-term operating activity ratios reveals notable shifts over the five-year period. Generally, efficiency metrics demonstrate a weakening trend from 2021 through 2025, with some ratios exhibiting more pronounced changes than others. A consistent pattern of increasing days in key cycles is observed, suggesting a lengthening of the time required to convert investments into cash.

Inventory Management
Inventory turnover decreased substantially from 3.40 in 2021 to 1.51 in 2025. This indicates a growing inefficiency in managing inventory levels, with goods sitting longer before being sold. Correspondingly, the average inventory processing period increased from 107 days in 2021 to 242 days in 2025, confirming a slower inventory flow. The most significant decline in inventory turnover occurred between 2022 and 2023, and then again between 2023 and 2024.
Receivables Management
Receivables turnover initially improved from 7.16 in 2021 to 9.24 in 2022, but then declined to 5.27 by 2025. This suggests an initial improvement in collecting receivables, followed by a weakening ability to convert credit sales into cash. The average receivable collection period increased from 51 days in 2021 to 69 days in both 2023, 2024 and 2025, indicating a lengthening of the time it takes to receive payment from customers.
Payables Management
Payables turnover decreased from 5.53 in 2021 to 3.07 in 2025, suggesting a slower rate of paying suppliers. The average payables payment period increased from 66 days in 2021 to 119 days in 2025, indicating the company is taking longer to settle its obligations. This could be a strategic decision to manage cash flow, but also warrants investigation to ensure it does not strain supplier relationships.
Overall Operating Cycle & Cash Conversion
The operating cycle lengthened from 158 days in 2021 to 311 days in 2025, reflecting the combined effect of slower inventory turnover and receivable collection. The cash conversion cycle also increased significantly, moving from 92 days in 2021 to 192 days in 2025. This indicates a longer period between paying for inventory and receiving cash from sales, potentially tying up working capital and impacting liquidity.
Working Capital Efficiency
Working capital turnover experienced a substantial increase from 4.83 in 2021 to 11.09 in 2022, before decreasing to 10.58 in 2025. This suggests a period of improved efficiency in utilizing working capital, followed by a stabilization at a higher level than the initial value. The absence of a value for 2023 prevents a complete assessment of the trend.

In summary, the observed trends suggest a gradual decline in short-term operating efficiency. The increasing cycle times and decreasing turnover ratios warrant further investigation to identify the underlying causes and potential mitigation strategies.


Turnover Ratios


Average No. Days


Inventory Turnover

Pfizer Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of sales
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Inventory Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Inventory Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Inventory turnover = Cost of sales ÷ Inventories
= ÷ =

2 Click competitor name to see calculations.


An examination of the provided financial information reveals a notable trend in inventory turnover over the five-year period. The ratio demonstrates a fluctuating pattern, initially increasing before experiencing a substantial decline.

Inventory Turnover Trend
The inventory turnover ratio increased from 3.40 in 2021 to 3.82 in 2022, indicating a more efficient conversion of inventory into sales during that period. However, this positive trend reversed in subsequent years. A significant decrease was observed in 2023, with the ratio falling to 2.45. This downward trajectory continued into 2024 and 2025, reaching 1.65 and 1.51 respectively.

The decline in inventory turnover coincides with a decrease in cost of sales. While inventories remained relatively stable between 2021 and 2023, they increased in 2024 and 2025. The combination of decreasing cost of sales and relatively stable or increasing inventory levels directly contributes to the observed reduction in the inventory turnover ratio.

Cost of Sales and Inventory Relationship
Cost of sales decreased from US$30,821 million in 2021 to US$16,067 million in 2025. Inventories fluctuated, beginning at US$9,059 million in 2021, decreasing slightly to US$8,981 million in 2022, increasing to US$10,189 million in 2023, and then further to US$10,851 million in 2024 before decreasing slightly to US$10,654 million in 2025. The consistent decline in cost of sales, coupled with relatively stable inventory levels, suggests a potential shift in sales volume or product mix.

The decreasing inventory turnover ratio suggests that the entity is taking longer to sell its inventory. This could be due to a variety of factors, including reduced demand for products, increased competition, or inefficiencies in inventory management. Further investigation into the underlying causes of this trend is warranted.


Receivables Turnover

Pfizer Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Revenues
Trade accounts receivable, net of allowance for doubtful accounts
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Receivables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Receivables turnover = Revenues ÷ Trade accounts receivable, net of allowance for doubtful accounts
= ÷ =

2 Click competitor name to see calculations.


The receivables turnover ratio exhibits considerable fluctuation over the observed period. Initially, the ratio increased significantly, followed by a substantial decline and subsequent stabilization at a lower level.

Receivables Turnover Trend
The receivables turnover ratio increased from 7.16 in 2021 to 9.24 in 2022, indicating improved efficiency in collecting receivables. This suggests a faster conversion of credit sales into cash during this period. However, a marked decrease occurred in 2023, with the ratio falling to 5.33. This decline persisted into 2024, with a slight increase to 5.55, before decreasing again to 5.27 in 2025.

The increase in 2022 coincided with a significant rise in revenues. The subsequent declines in the receivables turnover ratio, despite relatively stable revenue figures in 2023, 2024, and 2025, suggest a potential slowdown in the collection process. This could be due to changes in credit terms offered to customers, a shift in the customer base, or increased difficulties in collecting outstanding balances.

Relationship to Revenues
Revenues increased substantially from 2021 to 2022, but then decreased significantly in 2023. Revenues remained relatively stable between 2023 and 2025. The initial increase in revenues appears to have been accompanied by an improvement in receivables collection efficiency, as evidenced by the rise in the turnover ratio. However, the subsequent decline in revenues did not result in a corresponding increase in the turnover ratio, and the ratio continued to decrease, suggesting that factors beyond revenue levels are influencing collection efficiency.

Trade accounts receivable remained relatively stable throughout the period, fluctuating between approximately US$10.95 billion and US$11.87 billion. The combination of stable receivables and fluctuating revenues is a key driver of the observed changes in the receivables turnover ratio.

Potential Implications
The declining receivables turnover ratio from 2022 to 2025 warrants further investigation. A lower ratio may indicate a greater proportion of credit sales are outstanding for extended periods, potentially increasing the risk of bad debts and tying up working capital. Management should assess the effectiveness of its credit and collection policies and procedures.

Payables Turnover

Pfizer Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cost of sales
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Payables Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Payables turnover = Cost of sales ÷ Trade accounts payable
= ÷ =

2 Click competitor name to see calculations.


An examination of the provided financial information reveals a declining trend in payables turnover over the five-year period. This suggests a lengthening of the time it takes the company to pay its suppliers. Simultaneously, cost of sales demonstrates a significant decrease from 2021 to 2024, followed by a more moderate decrease in 2025, while trade accounts payable exhibits a more stable pattern.

Payables Turnover
The payables turnover ratio decreased consistently from 5.53 in 2021 to 3.07 in 2025. The most substantial decline occurred between 2022 and 2023, falling from 5.04 to 3.72. The rate of decline slowed between 2023 and 2025, but the overall trend remains downward. This indicates the company is taking longer to settle its obligations to suppliers.
Cost of Sales
Cost of sales experienced a notable increase from 2021 to 2022, rising from US$30,821 million to US$34,344 million. However, a significant decrease followed, with cost of sales falling to US$24,954 million in 2023, US$17,851 million in 2024, and US$16,067 million in 2025. This substantial reduction may be attributable to various factors, including changes in production volume, sourcing strategies, or product mix.
Trade Accounts Payable
Trade accounts payable increased from US$5,578 million in 2021 to US$6,809 million in 2022, before stabilizing around US$6,710 million in 2023. A moderate decrease was observed in 2024 and 2025, with values of US$5,633 million and US$5,240 million respectively. The relative stability of payables, coupled with the declining cost of sales, contributes to the observed decrease in payables turnover.

The combination of decreasing cost of sales and relatively stable trade accounts payable suggests the company may be managing its purchasing and inventory levels more efficiently, or potentially experiencing reduced demand. The declining payables turnover warrants further investigation to determine if it reflects a deliberate strategy to optimize cash flow, or if it indicates potential issues with supplier relationships or payment processing.


Working Capital Turnover

Pfizer Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Revenues
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Working Capital Turnover, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Working capital turnover = Revenues ÷ Working capital
= ÷ =

2 Click competitor name to see calculations.


The working capital turnover ratio exhibited considerable fluctuation over the observed period. Initial values indicate a substantial increase followed by a period of unavailability and subsequent stabilization. A detailed examination of the components and the resulting ratio reveals key insights into the company’s operational efficiency.

Working Capital Trend
Working capital demonstrated a significant decrease from 2021 to 2022, falling from US$17,022 million to US$9,121 million. This decline continued into 2023, resulting in a negative working capital position of US$4,461 million. A recovery was observed in 2024, with working capital increasing to US$7,363 million, and this positive trend continued modestly into 2025, reaching US$5,914 million. The shift to negative working capital in 2023 is a notable event requiring further investigation.
Revenue Trend
Revenues increased substantially from 2021 to 2022, rising from US$82,145 million to US$101,175 million. However, a significant decrease in revenues occurred in 2023, with revenues falling to US$59,553 million. Revenues experienced a moderate increase in 2024 to US$63,627 million, followed by a slight decrease in 2025 to US$62,579 million. The revenue decline in 2023 coincides with the period of negative working capital.
Working Capital Turnover Ratio
The working capital turnover ratio increased dramatically from 4.83 in 2021 to 11.09 in 2022, indicating a more efficient utilization of working capital to generate revenue. The ratio was not calculated for 2023, likely due to the negative working capital balance. The ratio recovered to 8.64 in 2024 and further increased to 10.58 in 2025. The 2024 and 2025 values, while positive, remain below the peak observed in 2022. The absence of a ratio calculation in 2023 highlights the impact of negative working capital on this metric.

The interplay between working capital and revenues significantly influences the working capital turnover ratio. The substantial revenue growth in 2022, coupled with a decrease in working capital, drove the significant increase in the ratio. The subsequent revenue decline and negative working capital in 2023 prevented ratio calculation. The recovery in both working capital and the ratio in 2024 and 2025 suggests a return to more stable operational conditions, although the ratio has not fully returned to its 2022 peak.


Average Inventory Processing Period

Pfizer Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Inventory Processing Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Inventory Processing Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average inventory processing period exhibited a notable trend over the five-year period. Initially, a decrease was observed, followed by a substantial and sustained increase. The inventory turnover ratio demonstrates an inverse relationship, declining concurrently with the lengthening processing period.

Average Inventory Processing Period
In 2021, the average inventory processing period was 107 days. This decreased to 95 days in 2022, representing a more efficient conversion of inventory into sales. However, beginning in 2022, the period began to lengthen considerably. By 2023, it had risen to 149 days, continuing to 222 days in 2024 and reaching 242 days in 2025. This indicates a progressively slower rate at which inventory is sold and replenished.
Inventory Turnover
The inventory turnover ratio began at 3.40 in 2021 and increased to 3.82 in 2022, aligning with the shorter average inventory processing period. A significant decline commenced in 2023, with the ratio falling to 2.45. This downward trend continued, reaching 1.65 in 2024 and further decreasing to 1.51 in 2025. The decreasing ratio suggests that inventory is being sold more slowly relative to average inventory levels.

The consistent inverse relationship between the average inventory processing period and the inventory turnover ratio suggests a fundamental shift in inventory management or demand patterns. The lengthening processing period, coupled with the declining turnover, warrants further investigation to determine the underlying causes, such as potential obsolescence, overstocking, or weakening demand for specific products.


Average Receivable Collection Period

Pfizer Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Receivable Collection Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An examination of short-term activity ratios reveals fluctuations in the efficiency of collecting receivables over the five-year period. Specifically, the receivables turnover ratio and the average receivable collection period demonstrate distinct trends.

Receivables Turnover
The receivables turnover ratio increased from 7.16 in 2021 to a peak of 9.24 in 2022, indicating improved efficiency in converting receivables into cash. However, this ratio then declined significantly to 5.33 in 2023, and remained relatively stable at 5.55 and 5.27 in 2024 and 2025, respectively. This suggests a weakening in the company’s ability to quickly collect receivables following the initial improvement.
Average Receivable Collection Period
Correspondingly, the average receivable collection period decreased from 51 days in 2021 to 40 days in 2022, aligning with the increased receivables turnover. A substantial increase was then observed in 2023, rising to 69 days. The period remained elevated at 66 days in 2024 and concluded at 69 days in 2025. This indicates a lengthening of the time required to collect receivables, potentially due to changes in credit policies, customer payment behavior, or collection efforts.

The observed trends suggest that while initial improvements were made in receivable management, the company experienced a reversal in efficiency beginning in 2023. The consistent collection period of 69 days in 2023 and 2025 warrants further investigation to determine the underlying causes and potential mitigation strategies.


Operating Cycle

Pfizer Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Operating Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Operating Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle lengthened considerably over the five-year period. Each component contributing to the cycle – average inventory processing period and average receivable collection period – exhibited changes that, in combination, drove the overall trend.

Average Inventory Processing Period
The average inventory processing period demonstrated an increasing trend. Starting at 107 days in 2021, it decreased to 95 days in 2022 before rising to 149 days in 2023. This increase continued through 2024, reaching 222 days, and further extended to 242 days in 2025. This suggests a growing inefficiency in managing inventory, potentially indicating overstocking, slower sales, or issues within the supply chain.
Average Receivable Collection Period
The average receivable collection period showed more moderate fluctuations. It decreased from 51 days in 2021 to 40 days in 2022, indicating improved efficiency in collecting payments from customers. However, it then increased to 69 days in 2023, remaining relatively stable at 66 days in 2024 and 69 days in 2025. While the initial improvement is positive, the subsequent stabilization at a higher level suggests potential challenges in maintaining optimal collection practices.
Operating Cycle
The operating cycle, calculated as the sum of the average inventory processing period and the average receivable collection period, increased consistently throughout the period. Beginning at 158 days in 2021, it decreased to 135 days in 2022. However, it then rose significantly to 218 days in 2023, 288 days in 2024, and peaked at 311 days in 2025. This lengthening cycle indicates that it is taking progressively longer to convert investments in inventory and receivables into cash, potentially tying up working capital and impacting liquidity.

The most substantial change occurred between 2022 and 2023, with both inventory processing and the overall operating cycle experiencing notable increases. The continued increases in the inventory processing period through 2025 are a primary driver of the extended operating cycle, warranting further investigation into inventory management practices.


Average Payables Payment Period

Pfizer Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Average Payables Payment Period, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An examination of the provided financial information reveals a consistent lengthening of the average payables payment period between 2021 and 2025. This trend is mirrored by a corresponding decrease in the payables turnover ratio over the same period.

Payables Turnover
The payables turnover ratio decreased from 5.53 in 2021 to 3.07 in 2025. This indicates a declining efficiency in paying suppliers. The rate of decline was more pronounced between 2021 and 2023 (a decrease of 1.81) than between 2023 and 2025 (a decrease of 0.15), suggesting a possible stabilization of this metric in the latter years.
Average Payables Payment Period
The average payables payment period increased steadily from 66 days in 2021 to 119 days in 2025. This signifies that the entity is taking progressively longer to settle its obligations to suppliers. Similar to the payables turnover, the largest increase occurred between 2021 and 2023 (an increase of 32 days), with more moderate increases observed in subsequent years (increases of 17 and 4 days respectively).

The observed trends suggest a potential shift in the entity’s payment strategy, possibly aimed at preserving cash flow. However, a prolonged increase in the payment period could potentially strain relationships with suppliers and may indicate increasing difficulty in meeting short-term obligations. Further investigation into the reasons behind these changes, including supplier terms and the entity’s overall liquidity position, would be beneficial.


Cash Conversion Cycle

Pfizer Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Conversion Cycle, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Conversion Cycle, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


An examination of short-term operating activity reveals notable shifts in key metrics between 2021 and 2025. The average inventory processing period, average receivable collection period, average payables payment period, and the resulting cash conversion cycle all demonstrate distinct trends over the five-year period.

Average Inventory Processing Period
The average inventory processing period exhibited a decreasing trend from 107 days in 2021 to a low of 95 days in 2022. However, this was followed by a substantial increase, reaching 149 days in 2023, 222 days in 2024, and further increasing to 242 days in 2025. This suggests a lengthening of the time required to convert inventory into finished goods and ultimately, sales.
Average Receivable Collection Period
The average receivable collection period decreased from 51 days in 2021 to 40 days in 2022, indicating improved efficiency in collecting payments from customers. This metric then increased to 69 days in 2023, before stabilizing at 66 days in 2024 and 69 days in 2025. While still above the 2022 level, the recent stabilization suggests collection efforts have found a new equilibrium.
Average Payables Payment Period
The average payables payment period showed a gradual increase throughout the period. Starting at 66 days in 2021, it rose to 72 days in 2022, 98 days in 2023, 115 days in 2024, and 119 days in 2025. This indicates a lengthening of the time taken to pay suppliers, potentially reflecting a strategy to preserve cash or negotiate more favorable payment terms.
Cash Conversion Cycle
The cash conversion cycle initially decreased significantly from 92 days in 2021 to 63 days in 2022, driven by improvements in both inventory management and receivable collection. However, the cycle then increased substantially, reaching 120 days in 2023, 173 days in 2024, and peaking at 192 days in 2025. This lengthening cycle is primarily attributable to the increasing inventory processing period, despite some stabilization in the receivable collection period and the extended payables payment period. The increasing cash conversion cycle suggests a growing need for working capital financing or a potential inefficiency in managing the flow of cash within the operating cycle.

Overall, the trends indicate a shift from improved operating efficiency in 2022 to a lengthening of the cash conversion cycle in subsequent years. The significant increase in the inventory processing period appears to be the primary driver of this change, warranting further investigation into the factors contributing to slower inventory turnover.